 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--- KALV--KalVista Pharmaceuticals, Inc. Nasdaq: KALV today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of 36.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be 193.5 million. In addition, KalVista has granted the underwriter 